Use of protein factor or nucleic acid encoding the protein factor, for suppressing the expression of genes encoding enzyme with alpha-1,6-fucosyltransferase activity, where the protein factor is e.g. transcription factor KLF15

摘要

Use of a protein factor or a nucleic acid encoding the protein factor, for suppressing the expression of one or more genes encoding an enzyme with alpha -1,6 fucosyltransferase activity, where the protein factor is a transcription factor KLF15, particularly mammalian, or its variant having an amino acid identity of at least 80% with the transcription factor KLF15 and preserving the modulation properties of the transcription of the transcription factor KLF15 and a fragment of the transcription factor KLF15, is claimed. Use of a protein factor or a nucleic acid encoding the protein factor, for suppressing the expression of one or more genes encoding an enzyme with alpha -1,6 fucosyltransferase activity, where the protein factor is a transcription factor KLF15, particularly mammalian or its variant having an amino acid identity of at least 80% with the transcription factor KLF15 and preserving the modulation properties of the transcription of the transcription factor KLF15 and a fragment of the transcription factor KLF15, provided that such fragment contains the domain of DNA-binding of the transcription factor KLF15 and preserves the modulation properties of the transcription of the transcription factor KLF15, is claimed. Independent claims are included for: (1) transgenic cell transformed by a nucleic acid encoding the protein factor, provided that such fragment contains the field of DNA-binding of the transcription factor KLF15 and preserves the repression properties of the transcription of the transcription factor KLF15, where the cells express the antibodies, particularly monoclonal antibodies; (2) composition comprising a culture medium comprising: one or more transgenic cells; and antibodies having a rate of fucosylation lower than antibodies produced by the cell from which transgenic cell is obtained; (3) YB2/0 transgenic cell transformed by a transcription factor KLF15; and (4) preparing monoclonal antibodies comprising: transformation of a transgenic cell or a cell of a cell line, such as YB2/0 by at least one nucleic acid allowing the expression of an antibody, where the transgenic cell is transformed by a nucleic acid encoding the protein factor.